Cycle Extends Expiration Date for Applied Therapeutics Tender Offer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Should l Buy APLT?
Source: Yahoo Finance
- Offer Extension: Cycle Group announces that AT2B has extended the expiration date of its tender offer for Applied Therapeutics from January 29, 2026, to February 2, 2026, indicating a sustained commitment to the acquisition that may enhance shareholder participation.
- Valid Tenders: As of January 29, 2026, approximately 75,895,437 shares of Applied have been validly tendered, representing about 49.21% of the outstanding shares, suggesting a high level of market acceptance for the transaction that could strengthen Cycle's market position.
- Acquisition Conditions: The successful execution of the offer is contingent upon fulfilling specific conditions, including the tender of a majority of the outstanding shares, reflecting Cycle's cautious and thorough approach to its acquisition strategy aimed at ensuring a smooth transaction completion.
- Transparency in Communication: Cycle has engaged MacKenzie Partners as the information agent to ensure shareholders receive necessary documents and information, enhancing transaction transparency and shareholder trust, which may encourage more shareholders to participate in the tender offer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLT
Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 0.25 USD with a low forecast of 0.25 USD and a high forecast of 0.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 0.103
Low
0.25
Averages
0.25
High
0.25
Current: 0.103
Low
0.25
Averages
0.25
High
0.25
About APLT
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cycle Extends Expiration Date for Applied Therapeutics Tender Offer
- Offer Extension: Cycle Group announces that AT2B has extended the expiration date of its tender offer for Applied Therapeutics from January 29, 2026, to February 2, 2026, indicating a sustained commitment to the acquisition that may enhance shareholder participation.
- Valid Tenders: As of January 29, 2026, approximately 75,895,437 shares of Applied have been validly tendered, representing about 49.21% of the outstanding shares, suggesting a high level of market acceptance for the transaction that could strengthen Cycle's market position.
- Acquisition Conditions: The successful execution of the offer is contingent upon fulfilling specific conditions, including the tender of a majority of the outstanding shares, reflecting Cycle's cautious and thorough approach to its acquisition strategy aimed at ensuring a smooth transaction completion.
- Transparency in Communication: Cycle has engaged MacKenzie Partners as the information agent to ensure shareholders receive necessary documents and information, enhancing transaction transparency and shareholder trust, which may encourage more shareholders to participate in the tender offer.
See More
RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
- Strong Financial Performance: RF Industries reported fourth-quarter net sales of $22.7 million, a 23% increase from $18.5 million a year earlier, indicating robust market performance that is likely to boost investor confidence.
- Significant Net Income Growth: The company achieved a non-GAAP net income of $2.1 million in Q4, translating to 20 cents per diluted share, a substantial increase from $394,000 or 4 cents per share in the same quarter last year, reflecting enhanced profitability.
- Stock Price Surge: Following the earnings report, RF Industries' shares jumped 21.4% to $8.76 in pre-market trading, indicating strong market optimism regarding the company's future growth potential, which may attract more investor interest.
- Quarterly Growth Trend: Compared to $19.8 million in sales for Q3 of fiscal 2025, the fourth-quarter sales increased by 15%, demonstrating the company's effective strategies in expanding market share and enhancing product demand.
See More
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
See More
Reasons Why Applied Therapeutics (APLT) Is an Excellent 'Buy the Dip' Stock at This Time
Stock Performance: Applied Therapeutics Inc. (APLT) shares have dropped 46.8% over the past week, but a hammer chart pattern suggests potential support and a possible trend reversal.
Technical Analysis: The hammer pattern indicates that selling pressure may be exhausting, and if it appears at the bottom of a downtrend, it signals that bears might be losing control.
Earnings Outlook: Recent upward revisions in earnings estimates, with a 1.9% increase in the consensus EPS estimate, indicate that analysts expect better performance from APLT, enhancing its bullish prospects.
Zacks Rank: APLT holds a Zacks Rank of #2 (Buy), placing it in the top 20% of stocks based on earnings estimate trends, which historically correlates with positive stock performance.
See More
Halper Sadeh Investigates A&B Sale to MW Group for $21.20 per Share
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Alexander & Baldwin, Inc. (NYSE: ALEX) for its sale to MW Group and funds affiliated with Blackstone Real Estate and DivcoWest at $21.20 per share, potentially violating federal securities laws and fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages A&B shareholders to understand their rights and options, potentially seeking increased consideration for shareholders or other relief measures to protect their interests.
- Merger Transaction Review: Halper Sadeh is also investigating Destination XL Group, Inc. (NASDAQ: DXLG) for its merger with FBB Holdings I, Inc., ensuring transparency and compliance throughout the transaction process.
- Potential Compensation Opportunities: The investigation extends to Applied Therapeutics, Inc. (NASDAQ: APLT), which is selling to Cycle Group Holdings Limited for $0.088 per share, with Halper Sadeh potentially advocating for additional compensation and disclosures for shareholders.
See More
S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 350 points, while the Dow and S&P 500 also experienced losses of 0.45% and 1.04%, respectively.
Broadcom's Strong Earnings: Broadcom Inc. reported fourth-quarter revenue of $18.02 billion, exceeding expectations, and announced a 10% increase in its quarterly cash dividend.
Notable Stock Movements: cbdMD Inc. shares surged 126% after compliance news, while Canopy Growth Corp. rose 38% on potential regulatory changes. Conversely, Applied Therapeutics Inc. fell 44% following acquisition news.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.53%, while Asian markets closed higher, led by Japan's Nikkei gaining 1.37%.
See More
Cycle Extends Expiration Date for Applied Therapeutics Tender Offer
- Offer Extension: Cycle Group announces that AT2B has extended the expiration date of its tender offer for Applied Therapeutics from January 29, 2026, to February 2, 2026, indicating a sustained commitment to the acquisition that may enhance shareholder participation.
- Valid Tenders: As of January 29, 2026, approximately 75,895,437 shares of Applied have been validly tendered, representing about 49.21% of the outstanding shares, suggesting a high level of market acceptance for the transaction that could strengthen Cycle's market position.
- Acquisition Conditions: The successful execution of the offer is contingent upon fulfilling specific conditions, including the tender of a majority of the outstanding shares, reflecting Cycle's cautious and thorough approach to its acquisition strategy aimed at ensuring a smooth transaction completion.
- Transparency in Communication: Cycle has engaged MacKenzie Partners as the information agent to ensure shareholders receive necessary documents and information, enhancing transaction transparency and shareholder trust, which may encourage more shareholders to participate in the tender offer.
See More
RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
- Strong Financial Performance: RF Industries reported fourth-quarter net sales of $22.7 million, a 23% increase from $18.5 million a year earlier, indicating robust market performance that is likely to boost investor confidence.
- Significant Net Income Growth: The company achieved a non-GAAP net income of $2.1 million in Q4, translating to 20 cents per diluted share, a substantial increase from $394,000 or 4 cents per share in the same quarter last year, reflecting enhanced profitability.
- Stock Price Surge: Following the earnings report, RF Industries' shares jumped 21.4% to $8.76 in pre-market trading, indicating strong market optimism regarding the company's future growth potential, which may attract more investor interest.
- Quarterly Growth Trend: Compared to $19.8 million in sales for Q3 of fiscal 2025, the fourth-quarter sales increased by 15%, demonstrating the company's effective strategies in expanding market share and enhancing product demand.
See More
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
See More
Reasons Why Applied Therapeutics (APLT) Is an Excellent 'Buy the Dip' Stock at This Time
Stock Performance: Applied Therapeutics Inc. (APLT) shares have dropped 46.8% over the past week, but a hammer chart pattern suggests potential support and a possible trend reversal.
Technical Analysis: The hammer pattern indicates that selling pressure may be exhausting, and if it appears at the bottom of a downtrend, it signals that bears might be losing control.
Earnings Outlook: Recent upward revisions in earnings estimates, with a 1.9% increase in the consensus EPS estimate, indicate that analysts expect better performance from APLT, enhancing its bullish prospects.
Zacks Rank: APLT holds a Zacks Rank of #2 (Buy), placing it in the top 20% of stocks based on earnings estimate trends, which historically correlates with positive stock performance.
See More
Halper Sadeh Investigates A&B Sale to MW Group for $21.20 per Share
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Alexander & Baldwin, Inc. (NYSE: ALEX) for its sale to MW Group and funds affiliated with Blackstone Real Estate and DivcoWest at $21.20 per share, potentially violating federal securities laws and fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages A&B shareholders to understand their rights and options, potentially seeking increased consideration for shareholders or other relief measures to protect their interests.
- Merger Transaction Review: Halper Sadeh is also investigating Destination XL Group, Inc. (NASDAQ: DXLG) for its merger with FBB Holdings I, Inc., ensuring transparency and compliance throughout the transaction process.
- Potential Compensation Opportunities: The investigation extends to Applied Therapeutics, Inc. (NASDAQ: APLT), which is selling to Cycle Group Holdings Limited for $0.088 per share, with Halper Sadeh potentially advocating for additional compensation and disclosures for shareholders.
See More
S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 350 points, while the Dow and S&P 500 also experienced losses of 0.45% and 1.04%, respectively.
Broadcom's Strong Earnings: Broadcom Inc. reported fourth-quarter revenue of $18.02 billion, exceeding expectations, and announced a 10% increase in its quarterly cash dividend.
Notable Stock Movements: cbdMD Inc. shares surged 126% after compliance news, while Canopy Growth Corp. rose 38% on potential regulatory changes. Conversely, Applied Therapeutics Inc. fell 44% following acquisition news.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.53%, while Asian markets closed higher, led by Japan's Nikkei gaining 1.37%.
See More
